(Q46380705)

21 December 2017

title

Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia (English)

1 reference

21 December 2017

main subject

chronic myeloid leukemia

0 references

leukemia

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

1 reference

Guowei Dai

1

1 reference

21 December 2017

Marc Pfister

series ordinal

2

1 reference

21 December 2017

Anne Blackwood-Chirchir

series ordinal

3

1 reference

21 December 2017

Amit Roy

series ordinal

4

1 reference

21 December 2017

publication date

8 September 2008

1 reference

21 December 2017

The Journal of Clinical Pharmacology

published in

1 reference

21 December 2017

volume

48

1 reference

21 December 2017

issue

11

1 reference

21 December 2017

page(s)

1254-1269

1 reference

21 December 2017

Learning versus confirming in clinical drug development

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Paving the critical path: how can clinical pharmacology help achieve the vision?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Clinical pharmacokinetics of capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Time-dependent oral absorption models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

The importance of modeling interoccasion variability in population pharmacokinetic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Model appropriateness and population pharmacokinetic modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

A pragmatic approach to the design of population pharmacokinetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Pharmacokinetics of ribavirin in patients with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008320604

21 January 2018

Identifiers

DOI

10.1177/0091270008320604

1 reference

21 December 2017

1 reference

21 December 2017